Developments in purine and pyridimidine receptor-based therapeutics

Drug Development Research

Volumn 39, Issue 3-4, 1996, Pages 436-441

  Spedding, Michael ^a   Williams, Michael ^b  

^a Science Reunion   (France)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Purine; Pyrimidine therapeutics

Indexed keywords

ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; PURINE P2 RECEPTOR; URIDINE TRIPHOSPHATE;

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; COGNITION; CONFERENCE PAPER; DRUG RESEARCH; HUMAN; KIDNEY DISEASE; METASTASIS; NONHUMAN; PAIN; PARKINSON DISEASE; RECEPTOR BINDING; SEPTIC SHOCK; STROKE;

EID: 0030436331     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199611/12)39:3/4<436::AID-DDR25>3.0.CO;2-Y     Document Type: Conference Paper

References (56)

1. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR (1996): The effect of uridine 5′-triphospliate plus amiloride on mucociliary clearence in adult cystic fibrosis. Am J Respir Crit Care Mod 153:1796-1801.
2. Bhagwat SS, Williams M (1997): P2 Purine and pyrimidine receptors: Emerging superfamilies of G-protein coupled and ligand gated ion channel receptors. Eur J Med Chem (in press).
3. Black JW (1989): Drugs from emasculated hormones: The principle of syntopic antagonism. Science 245:486-494.
4. 3 ligands controlling cytokines. Drug Dev Res 37:173.
5. 1 receptor. Mol Pharmacol 50:1323-1329.
6. Brake AJ, Julius D (1996): Signaling by extracellular micleotides. Annu Rev Cell Biol 12:519-541.
7. 2-purinoceptor subtypes and ecto-nucleotidases by small aromatic isothiocyanatosulphonates. Naunyn-Schmiedebergs Arch Pharmacol 354:481-490.
8. 2- purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn-Schmiedebergs Arch Pharmacol 354:498-504.
9. Burnstock G, King BF (1996): The numbering of cloned P2 purinoceptors. Drug Dev Res 38:67-71.
10. Burnstock G, Wood JN (1996): Pnririergic receptors: Their role in nociception and primary afferent neurotransmission. Curr Opin Neurobiol 6:526-532.
11. Cronstein BN, Naime D, Firestein G (1995): The antiinflammatory effects of an adensine kinase inhibitor are mediated by adenosine. Arthritis Rheum 38:1040-1045.
12. Cronstein BN, Bouma MG, Becker BF (1996): Purinergic mechanisms in inflammation. Drug Dev Res 39:426-435.
13. Denlinger LC, Fisette PL, Garis KA, Kwon G, Vazquez-Torres A, Simon AD, Nguyen B, Proctor RA, Beries PJ, Corbett JA (1996): Regulation of inducible nitric oxide synthase expression by macrophage purinoceptors and calcium. J Biol Chem 271:337-342.
14. 2B receptors evoke interleukin-8 secretion in human mast cells. J Clin Invest 96:1979-1986.
15. Feoktistov I, Biagionni I (1996): Role of adenosine in asthma. Drug Dev Res 39:333-336.
16. 2a-receptors. Glia 18:152-160.
17. Firestein GS (1996): Anti-inflammatory effects of adenosine kinase inhibitors in acute and chronic inflammation. Drug Dev Res 39:371-376.
18. Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, Sambol B, Mullane KM (1994): Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152:5853-5859.
19. Firestein GS, Bullough DA, Erion MD, Jiminez R, Ramirez-Weinhonse M, Barankiewicz J, Smith CW, Gruber HE, Mullane KM (1995): Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J Immunol 154:326-334.
20. Fisette PL, Denlinger LG, Proctor RA, Bertics PJ (1996): Modulation of macrophage function by P2Y purinergic receptors. Drug Dev Res 39:377-387.
21. Foster AJ, Reeve AJ, Lee Y-W, Yaksh TL, Dickenson AH, Schmitt E, Haywood C, Weisner JB (1997): Inhibitors of adenosine kinase reduce nociception in animal models of acute and chronic pain. (in press).
22. Foster HE, Hooper M, Spedding M, Sweetman AJ, Weetman DF (1978): Antagonism of the inhibitory effect of adenosine 5′-triphosphate on the isolated taenia of the guinea-pig, caecum: Structure-activity relationships within a series of isatogen derivatives. Br J Pharmacol 63:309-314.
23. Guieu R, Couraud F, Pouget J, Sampieri F, Bechis G, Rochat H (1996): Adenosine and the nervous system: Clinical implications. Clin Neuropharrnacol 19:459-474.
24. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES (1996): Adenosine receptor agonists differentially regulate IL-10, TNF-α and nitric oxide production in RAW 264.7 macophages and endotoxemic mice. J Immunol 157:4634-4640.
25. Hooper M, Spedding M, Sweetinan AJ, Weetman DF (1979): Effects of 2-2′-pyridylisatogcn on responses to adenosine 5′-triphosphate in isolated smooth muscle preparations. In Baer HP, Drummond GI (eds): Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides. New York: Raven, pp 85-93.
26. Humphries RG, Robertson MJ, Leff P (1995): A novel series of P2T purinoceptor antagonists: Definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 16:179-181.
27. 3 adenosine receptors: Design of selective ligands and therapeutic prospects. Drugs Future 20:689-699.
28. Jacobson KA, Suzuki F (1996): Recent developments in selective agonist and antagonists at purine and pyrimidine receptors. Drug Dev Res 39:289-300.
29. 3 adenosine receptor antagonists. Drug Dev Res 37:131.
30. King BF, Dacqnet C, Ziganshin AU, Weetman DF, Vanhoutte PM, Burnstock G, Spedding M (1996): Potentiation by 2,2′-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor. Br J Pharmacol 117:1111-1118.
31. Knutsen L, et al. (1997): J Med Chem (in press).
32. Lee C-H, Jiang M, Daanen J, Kohlass KL, Alexander KM, Yu H, Kowaluk EA, Bhagwat SS (1996): Synthesis and biological evaluation of clitocine analogs as adenosine kinase inhibitors. In Abstracts of the 212th American Chemical Society Meeting, Orlando, FL, August 1996, MEDI 156.
33. Le Moine O, Stordeur P, Schandene L, Marchant A, De Croot D, Goldman M, Deviere J (1996): Adenosine enhances IL-10 release from human monocytes. J Immunol 156:4408-4414.
34. Lonbatieres-Mariani MM, Petit P, Chapal J, Hillaire-Buys D, Bertrand G, Ribes G (1995): Effects of purinoceptor agonists on insulin secretion. In Bellardinelli L, Pelleg A (eds): Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Boston: Kluwer, pp 337-345.
35. Mangano DT and the Multicenter Study of Perioperative Ischemia (McSPI) Research Group (1997): Effects of acadesine on myocardial infarction, stroke, and death following surgery. JAMA 277:325-332.
36. Michel AD, Miller KJ, Buell G, Lundstrom K, Humphrey PPA (1996): Direct labelling of P2X purinoceptor subtypes. Drug Dev Res 37:113.
37. Mullane K, Young M (1993): Acadesine: Prototype adenosine regulating agent for treating myocardial ischemia-reperfusion injury. Drug Dev Res 28:336-343.
38. Nichols CG, Shyng S-L, Nestorowicz A, Glaser B, Clement JP IV, Gonzalez G, Aguilar-Bryan L, Pernnitt MA, Bryan J (1996): Adenosine diphosphate as an intracellular regulator of insulin secretion. Science 272:1785-1787.
39. North RA (1996): P2X purinoceptor plethora. Semin Neurosci 8:187-194.
40. 2A receptors. Trends Pharmacol Sci 17:364-372.
41. Proctor RA, Denlinger LC, Leventhal PS, Daugherty SK, van der Loo J-W, Tanke T, Firestein GS, Bertics PJ (1994): Protection of mice from endotoxic shock by 2-methylthio-ATP. Proc Natl Acad Sci USA 91:6017-6020.
42. Rapaport E (1993): Anticancer activities of adenine nucleotides in tumor bearing hosts. Drug Dev Res 28:428-131.
43. Rosengren S, Bong GW, Firestein GS (1995): Anti-inflammatory effects of an adenosine kinase inhihitor. Decreased neutrophil accumulation and vascular leakage. J Immunol 154:5444-5451.
44. Rosengren S, Bong GW, Firestein GS (1996): Spinal cord adenosine receptor stimulation in rats inhibits dermal neutrophil accumulation. The role of N-methyl-D-aspartate receptors. J Clin Invest 98:(in press).
45. 2 in rats. Proc Natl Acad Sci USA 93:5980-5984.
46. Spedding M, Weetman DF (1976): Identification of separate receptors for adenosine and adenosine 5′-triphosphate in causing relaxations of the isolated taenia of the guinea-pig caecum. Br J Pharmacol 57:305-310.
47. Spedding M, Weetman DF (1978a): The mechanism of the relaxant effect of 2-2′pyridylisatogen on the isolated taenia of the guinea-pig caecum. Br J Pharmacol 63:659-664.
48. Spedding M, Weetman DF (1978b): The problems associated with the use of 2-2′pyridylisatogen tosylate in evaluating the allegedly purinergic innervation of peripheral organs. J Pharm Pharmacol 28:335-336.
49. Spedding M, Sweetman AJ, Weetman DF (1975): Antagonism of adenosine 5′triphosphate-induced relaxation by 2-2 pyridylisatogen in the taenia of guinea-pig caecum. Br J Pharmacol 53:575-583.
50. 2U agonists induce chemotaxis nad actin polymerization in human neutrophils and differentiated HL60 cells. J Biol Chem 271:15597-15601.
51. Williams M (1993): Purinergic drags: Opportunities in the 1990s. Drug Dev Res 28:438-444.
52. 2-Purinoceptors: Localisation, Function and Transduction Mechanisms. CIBA Foundation Symposium 198. Chichester, UK: Wiley, pp 309-321.
53. Williams M, Burnstock G (1997): Purinergic neuromodulation: An historical overview. In Jacobson KA, Jarvis MF (eds): Purinergic Approaches in Experimental Therapeutics. New York: Wiley-Liss (in press).
54. 2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue. Naunyn-Schmiedebergs Arch Pharmacol 354:491-497.
55. Ziv I, Zilkha-Falb R, Offen D, Shirvan A, Barzilai A, Melamed E (1997): Levodopa induces apoptosis in cultured neuronal cells - A possible accelerator of nigrostriatal degeneration in Parkinson's disease? Mov Disord 12:17-23.
56. 2A adenosine receptor antagonist. J Pharmacol Exp Ther 276:398-404.